Abivax's Ulcerative Colitis Victory Marred by Cancer Shadow as Investors Weigh Divergent Analyst Views

Abivax's obefazimod shows strong efficacy in UC maintenance therapy, but seven cancer cases in the 50mg dose trigger sell-off, analyst divergence, and FDA scrutiny.

The biotech sector’s perennial tug-of-war between promising clinical data and safety signals is playing out in real time at Abivax. Its stock has stabilised after a violent sell-off triggered by mixed Phase?3 results for lead drug candidate obefazimod, but the recovery remains fragile. Shares changed hands at €90.40 on Friday, a modest 1.6% gain from the previous close, yet the weekly loss still stands at 20.3% and the year-to-date decline at 21.5%. Earlier in the week, a bounce pushed the stock above $105 — a 16% rally from the panic low — following the 40% plunge on 2?June.

The turbulence stems from the ABTECT maintenance therapy study in ulcerative colitis, which delivered unambiguous efficacy. Clinical remission rates at week?44 reached 50.8% on the 25?mg dose and 51.3% on the 50?mg dose, versus just 10.4% in the placebo arm. Those numbers would normally have fuelled a rally. Instead, the market fixated on the safety data: eight cancer cases emerged across the study, seven of them in the 50?mg group. Four of those were skin cancers, while one case occurred in the 25?mg arm. Abivax and its investigators maintain that the malignancies are not treatment-related and point to the absence of an organ-specific pattern. So far, that argument has failed to reassure investors.

Analysts remain sharply divided over how to price the risk. Jefferies downgraded the stock to Hold with a $90 price target, citing the cancer signal as a potential commercial headwind. At the other end of the spectrum, Citizens has set a $187 target, Wolfe Research uses $136, and Morgan Stanley is at $132 — a spread that reflects the deep uncertainty about the regulatory path ahead. The core question is whether the FDA will require a black?box warning or convene an advisory committee before approving obefazimod.

Financially, Abivax is in no immediate distress. The company ended the latest reporting period with around €491.6?million in cash and more than €480?million in working capital, which management says funds operations into the fourth quarter of 2027. That runway buys time to address the safety concerns before the planned FDA submission in late 2026. A detailed safety update is expected as early as this month, and the company has promised to provide a thorough explanation of the cancer cases.

The legal front is also heating up. The law firm Levi & Korsinsky has launched an investigation into whether Abivax adequately disclosed the safety risks from the Phase?3 trial before the data release. Such probes are common after steep biotech declines, but they add a layer of reputational and financial risk that management can ill afford.

Beyond ulcerative colitis, Abivax is also developing obefazimod for Crohn’s disease. Topline results from a Phase?2b induction study are due by mid?2027. For now, though, the spotlight remains firmly on the 50?mg dose and how the FDA will interpret the malignancy signal. Until that clarity arrives, the stock is likely to remain a high?volatility bet on a single compound’s risk?reward equation.